<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000400019</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20210004000019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Manejo a diferentes niveles de la neutropenia secundaria a glucogenosis: a propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Management at different levels of neutropenia secondary to glycogenosis: a case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Sierra]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Briceño-Casado]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Doctor José Molina Orosa Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Arrecife Las Palmas]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General Nuestra Señora del Prado Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Talavera de la Reina Toledo]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>4</numero>
<fpage>431</fpage>
<lpage>432</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000400019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000400019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000400019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La glucogenosis tipo Ib es una patología metabólica rara de carácter hereditario originada por deficiencias en el transportador microsomal de glucosa-6-fosfatasa. Considerando la baja incidencia de esta enfermedad, los casos clínicos suponen la fuente principal de información sobre su manejo. La neutropenia secundaria a la glucogenosis tipo Ib se asocia con la aparición de infecciones y enfermedad inflamatoria intestinal. El tratamiento es la administración de factores estimulantes de colonias (CSF) diariamente. La literatura previa describe la caída abrupta e inmediata del recuento de neutrófilos tras la interrupción del tratamiento con CSF. Se presenta el caso clínico de una mujer tratada con filgrastim cada 48 horas a dosis menores que no ha sido descrita previamente, estabilizando el recuento de neutrófilos por encima de 1 x 109 células/L sin aparición de infecciones. Por otra parte, se muestra el impacto negativo del contacto público, junto a medidas adoptadas que evitaron la aparición de infecciones durante la pandemia de la COVID-19. Por tanto, este caso clínico puede aportar información a diferentes niveles sobre el manejo de los pacientes con glucogenosis tipo Ib.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Glycogen storage disease type Ib is a rare hereditary metabolic pathology caused by deficiencies in the microsomal transporter of glucose-6-phosphatase. Considering the low incidence of this disease, clinical cases are the main source of information on its management. Neutropenia secondary to glycogenosis type Ib is associated with the appearance of infections and inflammatory bowel disease. The treatment is daily administration of colony stimulating factors (CSF). Previous literature describes the abrupt and immediate drop in the neutrophil count after discontinuation of CSF treatment. We present a case of a woman treated with filgrastim every 48 hours using a lower dose that has not been previously described. The neutrophil count was stabilized above 1 x 109 cells/L without the appearance of infections. On the other hand, the negative impact of public contact along with measures to prevent the appearance of infections during the COVID-19 pandemic was showed. Therefore, this case report can provide information at different levels on the management of patients with glycogen storage disease type Ib.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Glucogenosis]]></kwd>
<kwd lng="es"><![CDATA[filgrastim]]></kwd>
<kwd lng="es"><![CDATA[neutropenia]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[Glycogenosis]]></kwd>
<kwd lng="en"><![CDATA[filgrastim]]></kwd>
<kwd lng="en"><![CDATA[neutropenia]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brzozowski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mazur-Bialy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pajdo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kwiecien]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bilski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zwolinska-Wcislo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis]]></article-title>
<source><![CDATA[Curr Neuropharmacol]]></source>
<year>2016</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>892-900</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kutikov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Horwitz]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Uzzo]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A War on Two Fronts: Cancer Care in the Time of COVID-19]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
<volume>172</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>756-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Özen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glycogen storage diseases: New perspectives]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2007</year>
<volume>13</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2541-53</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaub]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heyne]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glycogen storage disease type Ib]]></article-title>
<source><![CDATA[Eur J Pediatr]]></source>
<year>1983</year>
<volume>140</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>283-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vannier]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Arnaud-Battandier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ricour]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buriot]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Griscelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic neutropenia and Crohn's disease in childhood. Report of 2 cases]]></article-title>
<source><![CDATA[Arch Fr Pediatr]]></source>
<year>1982</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>367-70</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roe]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Gilsanz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brief Report: Treatment of Chronic Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib with Colony-Stimulating Factors]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1992</year>
<volume>326</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>1666-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Diego-Fernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[García-Fernández]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Madrid]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Forte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous treatment with colony stimulating factors (G-CSF) for neutropenia associated with type Ib glycogenosis]]></article-title>
<source><![CDATA[An Esp Pediatr]]></source>
<year>2001</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>282-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoover]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[DuBois]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Samples]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[McCullough]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Chenaille]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of chronic enteritis in glycogen storage disease type IB with granulocyte colony-stimulating factor]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>1996</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>346-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="">
<source><![CDATA[Ficha técnica Neupogen 30 MU (0,3 mg/ml) solución inyectable]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="">
<source><![CDATA[Ficha técnica Imeth 15 mg/0,6 ml solución inyectable en jeringa precargada]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
